Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Rtw Biotech (RTW) Share News

IN BRIEF: RTW Biotech's largest private investment completes financing

23rd Jan 2026 11:23

RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Corxel Pharmaceuticals Ltd, RTW's largest private investment, has completed Series D-1 financing worth USD287 million. Says Corxel is a clinical-stage biopharmaceutical company developing therapies for cardiometabolic conditions, and its lead candidate, CX11, is an oral GLP-1 receptor agonist for obese and overweight patients currently in a phase 2 US trial. Expects the financing proceeds to support the advancement of this trial, as well as a planned global phase 2 trial in type 2 diabetes mellitus and initial preparations for phase 3 studies and other cardiometabolic programmes. Read More

IN BRIEF: RTW Biotech welcomes GSK deal to buy RAPT Therapeutics

21st Jan 2026 11:37

RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Notes GSK PLC's announcement on Tuesday that it has agreed to acquire RAPT Therapeutics Inc. Says RAPT, a Californian biopharmaceutical company developing therapies for inflammatory and immunologic diseases, represented 0.15% of its net asset value as of December 31. The all-cash transaction values RAPT at USD2.2 billion, with shareholders to receive USD58 per share. RTW says the price represents a 65% premium to RAPT's closing price on Monday. Read More

RTW Biotech's portfolio firm Penumbra acquired by Boston Scientific

16th Jan 2026 09:01

(Alliance News) - RTW Biotech Opportunities Ltd on Thursday noted Boston Scientific Corp's USD14.5 billion acquisition of Penumbra Inc, a portfolio company that represented 1.0% of its net asset value at the end of 2025. Read More

LONDON BRIEFING: Next redeems B shares; Johnson Service ups guidance

16th Jan 2026 07:56

(Alliance News) - Next confirms the redemption of B shares as part of its GBP421 million capital return, Johnson Service reports resilient 2025 trading with rising earnings, and Irish Residential Properties REIT announces a CFO transition. Read More

RTW Biotech portfolio firm Aktis raises USD318 million in US IPO

12th Jan 2026 11:08

(Alliance News) - RTW Biotech Opportunities Ltd on Monday said its portfolio company Aktis Oncology Inc has completed a USD318 million IPO on New York's Nasdaq, the first biotech listing of 2026. Read More

LONDON BRIEFING: British Land CEO to leave; Heathrow posts record year

12th Jan 2026 07:59

(Alliance News) - British Land CEO Simon Carter will step down after five years in the role, as Plus500 reports revenue and Ebitda ahead of expectations and Oxford Nanopore posts stronger-than-guided full-year sales growth, while Heathrow celebrates a record 84 million passengers in 2025. Read More

RTW Biotech invests USD5.9 million in Yarrow Bioscience funding round

18th Dec 2025 11:08

(Alliance News) - RTW Biotech Opportunities Ltd on Thursday said it participated in the series A funding round of clinical stage biotechnology company Yarrow Bioscience Inc ahead of its Nasdaq listing. Read More

LONDON MARKET OPEN: FTSE 100 slips despite European rally as SSE falls

4th Dec 2025 09:14

(Alliance News) - Stock prices in London were mixed on Thursday, as the FTSE 100 missed out on a European rally amid weakness in SSE and National Grid after Ofgem approved a GBP28 billion investment. Read More

LONDON BRIEFING: Ofgem approves GBP28 billion energy grid investment

4th Dec 2025 07:55

(Alliance News) - Rio Tinto says earnings could rise by up to 50% by 2030, SSE and National Grid welcome Ofgem's approval of GBP28 billion of energy investment and SSP swings to a loss. Read More

RTW Biotech notes investee Evommune's USD150 million IPO raise

7th Nov 2025 12:46

(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted one of its private portfolio companies Evommune Inc raised USD150 million in its initial public offering. Read More

RTW Biotech announces royalty funding agreement with Savara

31st Oct 2025 11:37

(Alliance News) - RTW Biotech Opportunities Ltd on Friday confirmed it has entered into a royalty funding agreement with clinical stage biopharmaceutical company Savara Inc for a rare lung disease treatment. Read More

RTW Biotech hails Novartis acquisition of investee Avidity

27th Oct 2025 11:41

(Alliance News) - RTW Biotech Opportunities Ltd on Monday noted that Swiss pharmaceutical major Novartis AG has definitively agreed to buy portfolio company Avidity Biosciences Inc. Read More

IN BRIEF: RTW Biotech Opportunities extends buyback by USD15 million

20th Oct 2025 10:34

RTW Biotech Opportunities Ltd - Guernsey-based investor in life sciences sector - Adds USD15 million to share buyback programme, aiming to close the discount of its share price to net asset value. RTW Biotech has USD5.8 million to complete from its current USD30 million buyback and will top that up by USD15 million, which is equivalent to about 9.2 million shares. Funds for the buyback come from several recent realisations of portfolio holdings. The company's most recently report net asset value, as of June 30, was USD1.70. Read More

RTW Biotech invests USD7.4 million in financing round for Kailera

15th Oct 2025 13:17

(Alliance News) - RTW Biotech Opportunities Ltd said on Wednesday that it invested USD7.4 million in Kailera Therapeutics Inc for the company's USD600 million Series B financing round. Read More

Akero says new owner Novo Nordisk to drive commercialisation process

10th Oct 2025 11:58

(Alliance News) - Akero Therapeutics Inc on Friday said it will benefit from "industry-leading development capabilities and commercial infrastructure" through its acquisition by Novo Nordisk AS. Read More

IN BRIEF: RTW Biotech lifts NAV on Biogen's USD85 million Alcyone deal

23rd Sep 2025 11:01

RTW Biotech Opportunities Ltd - Guernsey, Channel Islands-based investor in high-growth life science sectors - Notes Biogen Inc's agreement announced last Thursday to acquire portfolio company Alcyone Therapeutics Inc for USD85 million upfront plus milestone payments. Says the deal represents a 242% uplift on RTW's USD2.1 million carrying value of Alcyone, adding USD5.0 million, or around 0.7%, to its August 31 NAV, where Alcyone represented approximately a 0.3% position. Alcyone is developing ThecaFlex DRx, an implantable device for intrathecal delivery of neurological therapies, which Biogen plans to deploy with its marketed drug Spinraza, with a launch targeted in 2028. The transaction its RTW's second portfolio takeout this year, following Merck & Co Inc's purchase of Verona Pharma PLC, and says it highlights embedded value in its private holdings. Read More

RTW Biotech Opportunities NAV falls in "volatile" period for biotech

11th Sep 2025 10:29

(Alliance News) - RTW Biotech Opportunities Ltd on Thursday said the biotech industry is navigating a "complex but increasingly constructive environment" as it reported a decline in its interim net asset value per share. Read More

IN BRIEF: RTW Biotech Opportunities joins FTSE all-share index

5th Sep 2025 09:27

RTW Biotech Opportunities Ltd - Guernsey, Channel Islands-based investor in high-growth life science sectors - Says it will join the FTSE all-share index on September 22. This follows FTSE Russell's decision to include securities trading in non-sterling currencies. Chair William Simpson says the move "is likely to enhance our exposure to investors, develop greater UK and international investor awareness of RTW Bio, and provide increased long-term access to capital." Read More

UK earnings, trading statements calendar - next 7 days

4th Sep 2025 14:26

RTW Biotech joins Aquestive funding to support oral epinephrine

19th Aug 2025 10:05

(Alliance News) - RTW Biotech Opportunities Ltd on Tuesday noted Aquestive Therapeutics Inc's announcement of a strategic funding agreement with funds managed by RTW Investments LP. Read More

FTSE 100 Latest

Value10,223.54

Change51.78